Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023494 | PMC |
| http://dx.doi.org/10.1371/journal.ppat.1009383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Trap-Vaccinate-Release Protocol for Immunization of Skunks and Additional Rabies Vectors Against Rabies.
J Vis Exp
November 2024
US Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services;
Oral vaccination of wildlife against rabies via the distribution of vaccine-laden baits is used widely as a management tool in Europe and North America. Over the past several decades, successful programs have targeted important reservoirs, including coyotes, foxes, raccoon dogs, and raccoons, for prevention and control. However, other species (e.
View Article and Find Full Text PDFA novel inactivated oral rabies vaccine with the incorporation of U-OMP19 enhances the immunogenicity by reducing viral proteins degradation and activating dendritic cells in a mouse model.
Vet Microbiol
November 2024
National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; Hubei Hongshan Laboratory, Wuhan 430070, China; Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China; Frontiers Science Center for Animal Breeding and Sustainable Production, Huazhong Agricultural University, Wuhan, China. Electronic address:
Currently, dogs, especially stray dogs, and/or wild animals are the main sources of rabies transmission, and oral vaccination is the most practical way to control rabies in these animals. Safety and efficacy are two key criteria for developing oral vaccines. Concerning the efficacy of oral vaccines, degradation of immunogens by gastrointestinal fluid is a major challenge, resulting in suboptimal immune responses after vaccination.
View Article and Find Full Text PDFDevelopment of an ELISA for an effective potency determination of recombinant rabies human monoclonal antibody.
J Immunol Methods
November 2024
Dr. D.Y. Patil Biotechnology and Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth, Pune 411033, Maharashtra, India.
Article Synopsis
- The Rapid Fluorescence Focus Inhibition Test (RFFIT) measures the potency of rabies monoclonal antibodies, but is time-consuming and requires specialized facilities and trained personnel.
- The World Health Organization has encouraged the development of alternative methods, leading to the creation of an In-vitro ELISA test that uses inactivated rabies vaccine to quantify antibody potency.
- This new ELISA test is validated for accuracy and sensitivity, easy to perform, cost-effective, and can be conducted without the need for specialized labs, providing results in just a few hours.
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults.
Vaccine
December 2024
Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Article Synopsis
- Rabies remains a high-mortality disease, prompting the exploration of a novel vaccine called ChAd155-RG, which uses a genetically modified chimpanzee adenovirus vector to improve immunization logistics.
- A phase 1 clinical trial involving healthy adults compared the safety and immune response of ChAd155-RG to the standard vaccine, RabAvert, assessing factors like side effects and antibody levels.
- Results showed that while ChAd155-RG was generally safe, it demonstrated lower and less lasting antibody responses against rabies compared to RabAvert, possibly influenced by participants' preexisting immunity to the adenovirus vector used in the vaccine.
Rabies virus as vector for development of vaccine: pros and cons.
Front Vet Sci
September 2024
College of Veterinary Medicine, Qingdao Agricultural University, Qingdao, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!